Ortega Francisco José, Serrano Marta, Rodriguez-Cuenca Sergio, Moreno-Navarrete José María, Gómez-Serrano María, Sabater Mònica, Rodriguez-Hermosa Jose Ignacio, Xifra Gemma, Ricart Wifredo, Peral Belén, Vidal-Puig Antonio, Fernández-Real José Manuel
Department of Diabetes, Endocrinology and Nutrition (UDEN), Institut d'Investigació Biomèdica de Girona (IdIBGi), CIBERobn (CB06/03/010) and Instituto de Salud Carlos III (ISCIII), Carretera de França s/n, 17007, Girona, Spain,
J Mol Med (Berl). 2015 Jan;93(1):83-92. doi: 10.1007/s00109-014-1207-5. Epub 2014 Sep 25.
Transgenic overexpression of adipose tissue (AT) transducin-like enhancer of split 3 (TLE3) mimicked peroxisome proliferator-activated receptor gamma (PPARγ) agonists, improving insulin resistance in mice. This study aimed to investigate TLE3 gene expression (qRT-PCR) and protein (Western blot) in subjects with a wide spectrum of obesity and insulin sensitivity and in an independent cohort of obese subjects following surgery-induced weight loss. TLE3 was analyzed in human adipocytes and after treatment with rosiglitazone. Given the findings in humans, TLE3 was also investigated in mice after a high-fat diet (HFD) and in PPARγ knockout mice. Subcutaneous (SC) AT TLE3 was increased in subjects with type 2 diabetes (T2D). In fact, SC TLE3 was associated with increased fasting glucose (r = 0.25, p = 0.015) and S6K1 activity (r = 0.671, p = 0.003), and with decreased Glut4 (r = -0.426, p = 0.006) and IRS-1 expression (-31 %, p = 0.007) and activation (P-IRS-1/IRS-1, -17 %, p = 0.024). TLE3 was preferentially expressed in mature adipocytes and increased during in vitro differentiation in parallel to PPARγ. Weight loss led to improved insulin sensitivity, increased AT PPARγ and decreased TLE3 (-24 %, p = 0.0002), while rosiglitazone administration downregulated TLE3 gene expression in fully differentiated adipocytes (-45 %, p < 0.0001). The concept that TLE3 may act as a homeostatic linchpin in AT was also supported by its increased expression in HFD-fed mice (39 %, p = 0.013) and PPARγ knockout (74 %, p = 0.001). In summary, increased AT TLE3 in subjects with T2D and in AT from HFD-fed and PPARγ knockout mice suggest that TLE3 may play an adaptive regulatory role that improves AT function under decreased PPARγ expression.
TLE3 is expressed in mature adipocytes concomitantly with PPARγ. Subcutaneous adipose TLE3 is increased in T2D patients. Adipose TLE3 is upregulated in genetically ablated PPARγ and HFD-fed mice. TLE3 may be a homeostatic linchpin in insulin resistance and defective PPARγ.
脂肪组织中类转导素分裂增强子3(TLE3)的转基因过表达模拟了过氧化物酶体增殖物激活受体γ(PPARγ)激动剂的作用,改善了小鼠的胰岛素抵抗。本研究旨在调查广泛肥胖和胰岛素敏感性患者以及独立肥胖患者队列在手术诱导体重减轻后的TLE3基因表达(qRT-PCR)和蛋白质(蛋白质印迹法)情况。在人脂肪细胞中以及用罗格列酮处理后对TLE3进行了分析。鉴于在人类中的研究结果,还在高脂饮食(HFD)喂养的小鼠和PPARγ基因敲除小鼠中对TLE3进行了研究。2型糖尿病(T2D)患者的皮下(SC)脂肪组织中TLE3增加。事实上,SC TLE3与空腹血糖升高(r = 0.25,p = 0.015)和S6K1活性增加(r = 0.671,p = 0.003)相关,与Glut4降低(r = -0.426,p = 0.006)、IRS-1表达降低(-31%,p = 0.007)和激活降低(P-IRS-1/IRS-1,-17%,p = 0.024)相关。TLE3在成熟脂肪细胞中优先表达,并且在体外分化过程中与PPARγ平行增加。体重减轻导致胰岛素敏感性改善、脂肪组织PPARγ增加和TLE3降低(-24%,p = 0.0002),而给予罗格列酮可下调完全分化脂肪细胞中的TLE3基因表达(-45%,p < 0.0001)。TLE3可能在脂肪组织中作为稳态关键因素的概念也得到了其在HFD喂养小鼠(39%,p = 0.013)和PPARγ基因敲除小鼠(74%,p = 0.001)中表达增加的支持。
TLE3与PPARγ同时在成熟脂肪细胞中表达。T2D患者皮下脂肪TLE3增加。在基因敲除PPARγ的小鼠和HFD喂养的小鼠中脂肪组织TLE3上调。TLE3可能是胰岛素抵抗和PPARγ缺陷中的稳态关键因素。